StreetAlpha.app
Home › Stocks › MNPR

Monopar Therapeutics (MNPR)

$71.06
▼ −1.26%
LAST CLOSE · NOV 17

Monopar Therapeutics develops pharmaceutical drug candidates for Wilson disease and radiopharmaceutical cancer treatment. It last closed at $71.06 on Nov 17, down 1.26% on the day. The average 12-month price target from 2 analysts is $139.00 (+95.6% from the last close), with a high of $145.00 and a low of $133.00.

AI Auto Pilots
Is MNPR in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$0
Net income
−$20.6M
EPS (diluted)
−$2.44
Valuation
Market cap
$481.6M
6.8M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$52.6M
At Sep 30
Shareholder equity
$127.1M
Shares outstanding
6.8M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $0$0FY2024FY2025: $0$0FY2025

From MNPR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated MNPR in the past 90 days, not enough for a consensus
Average 12-month target
$139.00
▲ 95.6% upside

Based on 2 analysts who set a price target on MNPR in the past 90 days. The average target is $139.00, with a high of $145.00 and a low of $133.00, compared with the last close of $71.06.

Low $133.00Avg $139.00High $145.00
Blue marker: last close $71.06
Highest target$145.00
Average target$139.00
Lowest target$133.00
Latest rating changes
Morgan StanleyMaintained
Nov 16Buy$133
BarclaysTarget raised
Sep 11Buy$128 → $145
BarclaysMaintained
Aug 13Buy$128
Cantor FitzgeraldDowngrade
Aug 13Hold$119
BTIGTarget raised
Aug 12Buy$117 → $133
DateFirmActionRatingPrice target
Nov 16Morgan StanleyMaintainedBuy$133
Sep 11BarclaysTarget raisedBuy$128 → $145
Aug 13BarclaysMaintainedBuy$128
Aug 13Cantor FitzgeraldDowngradeHold$119
Aug 12BTIGTarget raisedBuy$117 → $133
Loading…

Technical Analysis

MNPR · as of the Nov 17 close · updated after every close
Turning down

The stock is 0% below its 20 day and 14% below its 50 day average. It is 9% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 44). The nearest support is the swing low (Oct 26) at $69.33, and the nearest resistance the Pivot at $71.21.

Short trendBearish
Long trendNeutral
MomentumNeutral
StretchNormal
VolatilityNormal, 6.9%/day
Key levels
$124.8252 week high+75.7%
$95.46100 day average+34.3%
$80.8250 day average+13.7%
$77.35200 day average+8.9%
$75.08Swing high (Oct 21)+5.7%
$73.04Pivot R1+2.8%
$71.3120 day average+0.4%
$71.21Pivot+0.2%
$71.06Last close
$69.33Swing low (Oct 26)−2.4%
$69.23Pivot S1−2.6%
$50.0752 week low−29.5%
Indicators
RSI (14)43.61Middle of its rangeNeutral
MACD-2.28Above its signal lineBullish
Stochastic38.3Middle of its rangeNeutral
ADX (14)23.9Weak trend
Williams %R-65.2Oversold below −80, overbought above −20Neutral
CCI (20)-9.8Oversold below −100, overbought above 100Neutral
Rate of change+1.7%Change over 10 sessionsBullish
ATR (14)$4.93Typical daily range, 6.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for MNPR

What happened before

See how MNPR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow MNPR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How MNPR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in MNPR in the last 90 days.

Loading…

See today’s whale options flow across the market →

MNPR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲64 buying vs 38 selling
  • ●Held by funds -0.1 pts
  • ▲Funds holding +10
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding10696+10.4%
In funds' top 1010–
Held by funds91.7%91.8%−0.1 pts
New / increased24 / 4028 / 32+6.7%
Reduced / sold out22 / 1624 / 140.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MNPR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MNPR is in one of them and how their past MNPR trades turned out.

MNPR in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MNPR in an article yet. Here's the latest on the wider market.

About Monopar Therapeutics

Monopar Therapeutics is a pharmaceutical company based in Wilmette, Illinois, that develops drug candidates. Its candidates include ALXN1840, licensed from AstraZeneca and in development for Wilson disease, and MNPR-101, which is being developed for radiopharmaceutical use in cancer treatment. The company relies on patents and licensed intellectual property to protect these candidates.

Headquarters
Wilmette, IL